Chronic liver disease (CLD) is a growing health concern which accounts for two million
deaths per year. Obesity, alcohol overconsumption, and progressive cholestasis are …

Abstract Background and Aims: Cholestasis is characterized by intrahepatic accumulation of
bile constituents, including bile acids (BAs), which promote liver damage. The apical sodium …

The liver is the most important organ for biological transformation in the body and is crucial
for maintaining the body's vital activities. Liver injury is a serious pathological condition that …

Peroxisome proliferator-activator receptors α/δ (PPARα/δ) are considered as potential drug
targets for cholestatic liver diseases (CLD) via ameliorating hepatic cholestasis …

Abstract Background & Aims Tropifexor (TXR) is a novel nonbile acid that acts as an agonist
of farnesoid X receptor (FXR). TXR is currently in Phase 2 trials for the treatment of non …

Background Adverse outcome pathway (AOP) networks are versatile tools in toxicology and
risk assessment that capture and visualize mechanisms driving toxicity originating from …

Multiple types of liver diseases, particularly cholestatic liver diseases (CSLDs) and biliary
diseases, can disturb bile acid (BA) secretion; however, BA accumulation is currently seen …

Chronic cholestatic liver diseases are characterized by injury of the bile ducts and
hepatocytes caused by accumulated bile acids (BAs) and inflammation. Wnt/β‐catenin …

Primary sclerosing cholangitis (PSC) is an idiopathic chronic immune-mediated cholestatic
liver disease characterized by fibro-inflammatory bile duct strictures, progressive …

Background Geniposide (GE), the active compound derived from Gardeniae Fructus,
possesses valuable bioactivity for liver diseases, but GE effects on bile duct ligation (BDL) …